Horizon Pharma Inc (NASDAQ:HZNP) 2017 Q3 Institutional Investor Sentiment Steady

January 21, 2018 - By Marguerite Chambers

 Horizon Pharma Inc (NASDAQ:HZNP)  2017 Q3 Institutional Investor Sentiment Steady

Sentiment for Horizon Pharma Inc (NASDAQ:HZNP)

Horizon Pharma Inc (NASDAQ:HZNP) institutional sentiment increased to 1 in Q3 2017. Its up 0.08, from 0.92 in 2017Q2. The ratio is more positive, as 83 investment professionals increased and started new stock positions, while 83 sold and reduced their stock positions in Horizon Pharma Inc. The investment professionals in our partner’s database now own: 132.29 million shares, up from 130.94 million shares in 2017Q2. Also, the number of investment professionals holding Horizon Pharma Inc in their top 10 stock positions increased from 3 to 5 for an increase of 2. Sold All: 33 Reduced: 50 Increased: 55 New Position: 28.

Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company has market cap of $2.47 billion. The companyÂ’s marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. It currently has negative earnings. The Company’s products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

The stock decreased 1.12% or $0.17 during the last trading session, reaching $15.04. About 1.26M shares traded. Horizon Pharma Public Limited Company (NASDAQ:HZNP) has declined 28.13% since January 21, 2017 and is downtrending. It has underperformed by 44.83% the S&P500.

Analysts await Horizon Pharma Public Limited Company (NASDAQ:HZNP) to report earnings on February, 26. They expect $0.22 EPS, down 56.00 % or $0.28 from last year’s $0.5 per share. HZNP’s profit will be $36.06 million for 17.09 P/E if the $0.22 EPS becomes a reality. After $0.26 actual EPS reported by Horizon Pharma Public Limited Company for the previous quarter, Wall Street now forecasts -15.38 % negative EPS growth.

Broadfin Capital Llc holds 5.81% of its portfolio in Horizon Pharma Public Limited Company for 3.10 million shares. Rhenman & Partners Asset Management Ab owns 3.01 million shares or 4.87% of their US portfolio. Moreover, Deerfield Management Co has 3.95% invested in the company for 6.92 million shares. The California-based Venbio Select Advisor Llc has invested 3.46% in the stock. Jw Asset Management Llc, a New York-based fund reported 270,775 shares.#img1#

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Coverage

Ratings analysis reveals 85% of Horizon Pharma’s analysts are positive. Out of 13 Wall Street analysts rating Horizon Pharma, 11 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $900 while the high is $40. The stock’s average target of $20.62 is 37.10% above today’s ($15.04) share price. HZNP was included in 54 notes of analysts from September 9, 2015. UBS maintained the stock with “Buy” rating in Thursday, November 30 report. The firm earned “Hold” rating on Monday, August 7 by Mizuho. Jefferies initiated it with “Buy” rating and $31 target in Tuesday, January 19 report. As per Tuesday, July 25, the company rating was maintained by Piper Jaffray. Mizuho maintained the shares of HZNP in report on Monday, August 28 with “Hold” rating. Piper Jaffray maintained it with “Buy” rating and $1800 target in Friday, July 14 report. The firm has “Buy” rating by Mizuho given on Friday, October 9. The firm has “Buy” rating given on Friday, October 13 by Piper Jaffray. The firm has “Neutral” rating given on Tuesday, August 9 by Citigroup. The stock has “Buy” rating by Cantor Fitzgerald on Monday, November 6.

More notable recent Horizon Pharma Public Limited Company (NASDAQ:HZNP) news were published by: Globenewswire.com which released: “Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” on January 05, 2018, also Globenewswire.com with their article: “Horizon Pharma plc Announces Availability of PROCYSBIâ„¢ (cysteamine bitartrate …” published on October 26, 2017, Globenewswire.com published: “Horizon Pharma plc Announces Agreement to License Pre-Clinical Uricase …” on January 08, 2018. More interesting news about Horizon Pharma Public Limited Company (NASDAQ:HZNP) were released by: Seekingalpha.com and their article: “Horizon Pharma: Primary Care Segment Remains A Burden And Should Be Sold” published on December 20, 2017 as well as Seekingalpha.com‘s news article titled: “Horizon Pharma Plc (HZNP) Q2 2017 Results – Earnings Call Transcript” with publication date: August 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: